目的 探讨当飞利肝宁胶囊联合聚乙二醇干扰素α-2a注射液治疗慢性乙型肝炎的临床疗效。方法 选取2016年9月—2018年3月在新疆医科大学第一附属医院治疗的82例慢性乙型肝炎患者作为研究对象，按照治疗方式的不同将患者分为对照组（43例）和治疗组（39例）。对照组皮下注射聚乙二醇干扰素α-2a注射液180 μg，1次/周。治疗组在对照组治疗基础上口服当飞利肝宁胶囊，4粒/次，3次/d。两组患者连续治疗6个月。观察两组患者的临床疗效，同时比较两组治疗前后的肝功能、肝纤维化指标、乙肝病毒脱氧核糖核酸（HBV DNA）和乙型肝炎E抗原（HbeAg）的转阴率。结果 治疗后，治疗组总有效率为92.31%，显著高于对照组的79.07%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者的天冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）和总胆红素（TBIL）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组肝功能水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组透明质酸（HA）、Ⅳ胶原蛋白（Ⅳ-C）和Ⅲ型前胶原肽（PCⅢ）水平显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组肝纤维化指标水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组患者HBV DNA转阴率、HBeAg转阴率显著高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 当飞利肝宁胶囊联合聚乙二醇干扰素α-2a注射液治疗慢性乙型肝炎疗效显著，可改善患者肝功能和肝纤维化程度，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Dangfei Liganning Capsules combined with Peginterferon α-2a Solution for injection in treatment of chronic hepatitis B. Methods Patients (82 cases) with chronic hepatitis B in the First Affiliated Hospital of Xinjiang Medical University from September 2016 to March 2018 were divided into control (43 cases) and treatment (39 cases) groups according to the different treatment methods. Patients in the control group were sc administered with Peginterferon α-2a Solution for injection 180 μg, once weekly. Patients in the treatment group were po administered with Dangfei Liganning Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, the liver function, the liver fibrosis indexes, HBV DNA and HbeAg negative rate in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 92.31%, which was significantly higher than 79.07% in the control group, and there were differences between two groups (P < 0.05). After treatment, the levels of AST, ALT, and TBIL in two groups were significantly decreased, and the difference was statistically significant in the same group (P< 0.05). After treatment, the liver function levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P< 0.05). After treatment, the levels of HA, Ⅳ-C, and PCⅢ in two groups were significantly decreased, and the difference was statistically significant in the same group (P< 0.05). After treatment, the liver fibrosis indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P< 0.05). After treatment, the negative rates of HBV DNA and HbeAg in the treatment group were significantly higher than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Dangfei Liganning Capsules combined with Peginterferon α-2a Solution for injection has a significant effect in treatment of chronic hepatitis B, can improve the liver function and liver fibrosis degree, which has a certain clinical application value.

新疆重大疾病医学重点实验室开放课题（SKLIB-XJMDR-2014-2）